U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Genetic Edge Compounds - 510403 - 06/05/2018
  1. Warning Letters

CLOSEOUT LETTER

Genetic Edge Compounds MARCS-CMS 510403 —

Recipient:
Genetic Edge Compounds

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
Office of Human and Animal Food Operations West Division 3
4040 North Central Expressway, Suite 300
Dallas, Texas 75204 

May 29, 2018

UPS OVERNIGHT

Bradley N. Howard, Owner and CEO
Genetic Edge Compounds, LLC
(b)(6), (b)(7)(C)
McKinney, Texas 75070

Mr. Howard:

The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter 2017-DAL-WL-15, dated April 14, 2017. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. If you choose to reestablish or sell your operations, the Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Jessica E. Hensley
Director, Compliance Branch
Office of Human and Animal Foods, West - Division 3 

Back to Top